Johann S de Bono

发表

Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer.

Rom Langerak, Koen Degeling, Maarten J. IJzerman, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Early oncology clinical trial design in the era of molecular-targeted agents.

Johann S de Bono, J. D. de Bono, R. Kristeleit, 2010, Future oncology.

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

Joaquim Bellmunt, Enrique Gallardo, Fred Saad, 2013, The Lancet. Oncology.

Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Johann S de Bono, Timothy A Yap, T. Yap, 2009, Clinical Cancer Research.

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

Keisuke Kuida, Dejan Juric, Serap Sankoh, 2017, Clinical Cancer Research.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

Tomasz Burzykowski, Arturo Molina, Marc Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Oliver Sartor, Susan Halabi, Lawrence H Schwartz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SPOP mutation leads to genomic instability in prostate cancer

Paola Lecca, Clarisse Marotz, Davide Prandi, 2015, eLife.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Wei Yuan, Nina Tunariu, Rosalind Eeles, 2015, The New England journal of medicine.

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Jan Lubinski, Alan Ashworth, Susan Shanley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

Noel W Clarke, Gerhardt Attard, Nicholas D James, 2014, European urology.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Mitch Dowsett, Gerhardt Attard, Johann S de Bono, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA Repair in Prostate Cancer: Biology and Clinical Implications.

Colin C Pritchard, Mark A Rubin, Christopher E Barbieri, 2017, European urology.

Utilizing circulating tumor cells: challenges and pitfalls.

Gerhardt Attard, Johann S de Bono, J. D. de Bono, 2011, Current opinion in genetics & development.

Increased survival with enzalutamide in prostate cancer after chemotherapy.

Kurt Miller, Fred Saad, Johann S de Bono, 2012, The New England journal of medicine.

Abiraterone and increased survival in metastatic prostate cancer.

Arturo Molina, Tina Cheng, Fred Saad, 2011, The New England journal of medicine.

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Xiaoyu Jia, Glenn Heller, Johann S de Bono, 2009, The Lancet. Oncology.